Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi Therapeutics (MGX) Accumulated Expenses (2023 - 2025)

Metagenomi (MGX) has disclosed Accumulated Expenses for 3 consecutive years, with $848000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 47.82% to $848000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $848000.0 through Dec 2025, down 47.82% year-over-year, with the annual reading at $848000.0 for FY2025, 47.82% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $848000.0 at Metagenomi, down from $3.9 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $11.5 million in Q4 2023, with the low at $674000.0 in Q1 2025.
  • Average Accumulated Expenses over 3 years is $5.7 million, with a median of $5.9 million recorded in 2025.
  • Peak annual rise in Accumulated Expenses hit 46.07% in 2025, while the deepest fall reached 90.48% in 2025.
  • Over 3 years, Accumulated Expenses stood at $11.5 million in 2023, then tumbled by 85.84% to $1.6 million in 2024, then tumbled by 47.82% to $848000.0 in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $848000.0, $3.9 million, and $5.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.